TT11

Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd line Hodgkin Lymphoma

Retrieved on: 
Venerdì, Giugno 16, 2023
Well, Hodgkin lymphoma, Cytokine release syndrome, CRS, Associate professor, Lymphoma, Malignancy, EOT, CHL, TT11, MD Anderson Cancer Center, International Conference on Population and Development, ASCT, Patient, Risk, University, PET/CT, Neoplasm, Therapy, CD30, ACTION, Conference, End, Safety, Bone marrow, Pharmaceutical industry, Medical imaging, Nivolumab

TT11 is currently being investigated in combination with Nivolumab in Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients after frontline therapy failure (NCT05352828).

Key Points: 
  • TT11 is currently being investigated in combination with Nivolumab in Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients after frontline therapy failure (NCT05352828).
  • Study protocol involves patients being treated with 2 cycles of Nivolumab, followed by a single infusion of CD30.CAR-T preceded by lymphodepletion (LD) chemotherapy.
  • A total of 15 patients were enrolled of which 13 were treated with Nivolumab + CD30 CAR-T therapy.
  • These results offer the potential to re-define Hodgkin lymphoma treatment paradigm, offering a second line treatment alternative free of transplant and high dose chemotherapy to patients who fail frontline therapy,” said Thomas Willemsen, President and CEO, Tessa Therapeutics.

Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano

Retrieved on: 
Martedì, Maggio 30, 2023
Epstein–Barr virus, Nivolumab, ICML, Lymphoma, Malignancy, CHL, TT11, International Conference on Machine Learning, Patient, Poster, Therapy, CD30, ACTION, Conference, Bone marrow, Pharmaceutical industry

TT11, is Tessa’s autologous CD30.CAR-T therapy currently being investigated in combination with Nivolumab in a Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients.

Key Points: 
  • TT11, is Tessa’s autologous CD30.CAR-T therapy currently being investigated in combination with Nivolumab in a Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients.
  • A poster providing first peak into data from this combination study will be presented at ICML, 2023.
  • TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
  • Details of the two presentations are as follows:
    17th International Conference on Malignant Lymphoma, Lugano

Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023

Retrieved on: 
Martedì, Gennaio 3, 2023
Epstein–Barr virus, Therapy, CFO, Optimism, Lymphatic system, Growth, Patient, Safety, Society, TT11, ASH, Pharmaceutical industry, Management, Polaris Partners

“I believe that this strategic refocus on our allogeneic platform positions the company at the forefront of CAR-T innovation during 2023 and beyond,” stated Thomas Willemsen, President and CEO of Tessa Therapeutics.

Key Points: 
  • “I believe that this strategic refocus on our allogeneic platform positions the company at the forefront of CAR-T innovation during 2023 and beyond,” stated Thomas Willemsen, President and CEO of Tessa Therapeutics.
  • During 2022, Tessa enhanced its executive management team with the appointment of Thomas Willemsen as President and CEO and Wilson W. Cheung as CFO.
  • Today, Tessa has announced that Steve Krognes will serve as the company’s new Chairman of the Board of Directors.
  • “We would like to extend our deepest gratitude to Dr. Ando for his leadership and contribution to the growth and development of Tessa.

Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma

Retrieved on: 
Lunedì, Dicembre 12, 2022
European Medicines Agency, EMA, University, CAR, PRIME, Oncology, Lymphatic system, Relapse, Hodgkin lymphoma, Food, FDA, Marketing, Poster, DNA, Lymphoma, Assistant professor, Priority, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TT11, Trial of the century, ASH, CD30, Hematological Cancer Research Investment and Education Act, CR, ORR, Neoplasm, CHL, Non-Hodgkin lymphoma, Stanford University, Associate professor, Research, Society, NHL, MD Anderson Cancer Center, Cancer, Therapy, Risk, Autotransplantation, Vaccine, Pharmaceutical industry, Patient

SINGAPORE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced updated clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy, were presented in a poster and oral podium presentation at the 64rd Annual Meeting of the American Society of Hematology (ASH). The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL). Moreover, research identified circulating tumor DNA (ctDNA) analysis as a potential measure of response in cHL after CD30 targeted CAR T-cell therapy.

Key Points: 
  • The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL).
  • The ASH poster, titled, “Updated Results and Correlative Analysis: Autologous CD30.CAR-T Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial),” reported expanded data from the pilot segment of a Phase 2 trial of autologous CD30.CAR-T in patients with r/r cHL.
  • “The data presented at ASH 2022 continue to demonstrate the CD30.CAR-T cell therapy to be well tolerated with excellent anti-tumor responses in patients with relapsed or refractory classical Hodgkin lymphoma.
  • Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma as both a monotherapy (Phase 2) and combination therapy (Phase 1b).

Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)

Retrieved on: 
Sabato, Dicembre 10, 2022
Infrastructure as code, Cell, Patient, PRIME, Baylor College of Medicine, Lymphatic system, Neoplasm, Hodgkin lymphoma, Center for Cell and Gene Therapy, FDA, Marketing, Safety, Cancer, Allotransplantation, TT11, Epstein–Barr virus, Toxic epidermal necrolysis, Trial of the century, ASH, CD30, European Medicines Agency, Hematological Cancer Research Investment and Education Act, Graft-versus-host disease, CHL, Baylor University, Gene therapy, Immune system, Society, GVHD, Therapy, Risk, Pharmaceutical industry, Doctor of Philosophy

SINGAPORE, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced enhanced clinical data from an ongoing Phase 1 study (NCT04288726) of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) therapy being co-developed by Baylor College of Medicine and Tessa. The results, detailed in an oral podium presentation at the 64th Annual Meeting of the American Society of Hematology (ASH) on December 10, demonstrated TT11X to be well-tolerated at all dosing levels, eliciting a 79% overall response rate and complete disappearance of tumor in six patients.

Key Points: 
  • An overall response rate of 79% (11/14 patients) was observed across all three dose levels, including six complete responses and six partial responses.
  • The strongest responses were achieved in patients treated at the higher dose levels with additional infusions resulting in increasing effectiveness.
  • “Importantly, CD30.CAR EBVSTs elicited a clinical response in 11 of 14 patients with advanced CD30-positve Hodgkin lymphoma including six complete responses.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.

Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform

Retrieved on: 
Lunedì, Novembre 7, 2022
Company, Lymphatic system, Private Securities Litigation Reform Act, Baylor College of Medicine, TT11, Hodgkin lymphoma, Center for Cell and Gene Therapy, Cell, Infrastructure as code, GLOBE, PRIME, European Medicines Agency, Graft-versus-host disease, FDA, Baylor University, Hematological Cancer Research Investment and Education Act, Neoplasm, Allotransplantation, Therapy, Trial of the century, Marketing, Epstein–Barr virus, Gene therapy, Cancer, Risk, GVHD, Technology, Center, Patient, Pharmaceutical industry

SINGAPORE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the execution of an exclusive agreement with Baylor College of Medicine for worldwide commercial rights to the allogeneic Epstein-Barr virus specific T-cell (EBVST) technology platform developed jointly by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. at Baylor College of Medicine. Tessa is currently advancing a pipeline of products that utilize CD30.CAR-modified EBVSTs, including its lead allogeneic cell therapy, TT11X, which is being co-developed for the treatment of relapsed or refractory CD30-positive lymphomas.

Key Points: 
  • CD30.ALLO Virus specific T-cells (VSTs) are highly specialized T cells that can recognize CD30+ tumors.
  • During the development of the allogeneic technology platform, Tessa and Baylor College of Medicine had an exclusive option agreement for commercial rights to the technology.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility.

Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition

Retrieved on: 
Giovedì, Novembre 3, 2022
Haematopoietic system, Lymphatic system, Private Securities Litigation Reform Act, DNA, Baylor College of Medicine, Hodgkin lymphoma, Society, Clinical Lymphoma, Myeloma & Leukemia, PRIME, FDA, Marketing, Graft-versus-host disease, Clinical trial, MD Anderson Cancer Center, Hematological Cancer Research Investment and Education Act, Department, Company, Neoplasm, 2021 Essex County Council election, GLOBE, Trial of the century, Ernest, ASH, Plasma, Epstein–Barr virus, CEO, Gene therapy, Cancer, PD, GVHD, Research, European Medicines Agency, Baylor University, Center for Cell and Gene Therapy, Relapse, Holm–Bonferroni method, TT11, Stanford University, Cell, Safety, Therapy, CD30, Risk, Center, CHL, Pharmaceutical industry, Vaccine, Patient, Doctor of Philosophy

TT11X, Tessas allogeneic off-the-shelf cell therapy, is based on Tessas proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.

Key Points: 
  • TT11X, Tessas allogeneic off-the-shelf cell therapy, is based on Tessas proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
  • An abstract highlighting updated data from the ongoing Phase 1/2 study of TT11X (BESTA) in CD30-positive lymphomas will be featured in an oral podium presentation at ASH 2022.
  • We are honored that ASH has accepted three abstracts involving Tessas autologous and allogeneic CD30.CAR-T therapies, including two oral podium presentations, at its prestigious annual meeting, stated Thomas Willemsen, President and CEO of Tessa Therapeutics.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.

Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022

Retrieved on: 
Mercoledì, Novembre 2, 2022
Marketing, Hodgkin lymphoma, Lotte New York Palace Hotel, TT11, Trial of the century, European Medicines Agency, PRIME, Hematological Cancer Research Investment and Education Act, Private Securities Litigation Reform Act, Cancer, Company, Therapy, FDA, Pharmaceutical industry

Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.

Key Points: 
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency.
  • Tessa is also advancing an allogeneic off-the-shelf cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR.
  • Tessa has its global headquarters in Singapore, where the company has built a state-of-the-art, commercial cell therapy manufacturing facility.

Tessa Therapeutics to Participate in 2nd Annual Needham Biotech Private Company 1x1 Forum

Retrieved on: 
Giovedì, Ottobre 6, 2022
TT11, Therapy, PRIME, Hodgkin lymphoma, Private Securities Litigation Reform Act, Trial of the century, Company, Marketing, CEO, European Medicines Agency, GLOBE, Lymphatic system, FDA, Cancer, Hematological Cancer Research Investment and Education Act, Pharmaceutical industry

SINGAPORE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that Thomas Willemsen, President and CEO, Wilson W. Cheung, Chief Financial Officer, and Ivan D. Horak, M.D., Chief Medical Officer and Chief Scientific Officer, will participate in the 2nd Annual Needham Biotech Private Company 1x1 Forum being held virtually October 18-19 2022.

Key Points: 
  • SINGAPORE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that Thomas Willemsen, President and CEO, Wilson W. Cheung, Chief Financial Officer, and Ivan D. Horak, M.D., Chief Medical Officer and Chief Scientific Officer, will participate in the 2nd Annual Needham Biotech Private Company 1x1 Forum being held virtually October 18-19 2022.
  • Details for the conference are as follows:
    Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • TT11 has been granted RMAT designation by the FDA and access to the PRIME scheme by European Medicine Agency.
  • Tessa has its global headquarters in Singapore, where the company has built a state-of-the-art, commercial cell therapy manufacturing facility.

Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022

Retrieved on: 
Mercoledì, Settembre 14, 2022
European Medicines Agency, Holm–Bonferroni method, Trial of the century, PRIME, Risk, FDA, Neoplasm, GVHD, Company, Private Securities Litigation Reform Act, Hodgkin lymphoma, Therapy, Patient, Baylor University, Technology, Cell, Graft-versus-host disease, Lymphatic system, Hematological Cancer Research Investment and Education Act, Infrastructure as code, TT11, GLOBE, Epstein–Barr virus, Marketing, Immune system, Cancer, Toxicity, Baylor College of Medicine, Pharmaceutical industry

SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the companys allogeneic off-the-shelf CD30.CAR EBVST cell therapy, has been recognized in the Most Promising Off-the-Shelf Therapies category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 .

Key Points: 
  • SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the companys allogeneic off-the-shelf CD30.CAR EBVST cell therapy, has been recognized in the Most Promising Off-the-Shelf Therapies category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 .
  • The ACGTEA 2022 Awards were held in conjunction with the 6th Cell & Gene Therapy World Asia 2022.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility.